First Patient Enrolled in Merit Medical's WRAPSODY ( WRAP ) North America Registry
SOUTH JORDAN, Utah, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Merit Medical Systems, Inc. ( NASDAQ: MMSI ) , a global leader of healthcare technology, announced today the successful enrollment of the first patient in the WRAP North America registry.
Merit Medical ( MMSI ) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength
HOLX targets a mid-single-digit organic growth rebound in 2026, powered by Breast Health recovery and new product innovation.
Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology - Merit Medical Systems ( NASDAQ:MMSI )
SOUTH JORDAN, Utah, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Merit Medical Systems, Inc. MMSI, a global leader of healthcare technology, today announced the US commercial release of the Prelude Wave™ Hydrophilic Sheath Introducer with SnapFix™ Securement Technology.
Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology
Thin-wall design with superior insertion and unique sheath-securement solution to support successful radial access procedures and may aid in reducing arterial spasm and occlusion Thin-wall design with superior insertion and unique sheath-securement solution to support successful radial access ...
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merit Medical ( MMSI ) Q2 Revenue Up 13%
Merit Medical Systems ( NASDAQ:MMSI ) , a medical device developer serving cardiovascular and endoscopy markets, reported results for its second quarter ended June 30, 2025, on July 30, 2025. The company posted GAAP revenue of $382.5 million, up 13.2% from the prior year and above the analyst ...
Merit Medical Q2 Earnings Beat Estimates, Gross Margin Expands
MMSI beats second-quarter 2025 earnings estimates as gross margin expands and strong U.S. and Cardiovascular sales drive revenue growth.
3 Small-Cap Growth Mutual Funds for Outstanding Returns
Below, we share with you three top-ranked small-cap growth mutual funds. Each has a Zacks Mutual Fund Rank #1 (Strong Buy).
What's Driving the Market Sentiment Around Merit Medical Systems? - Merit Medical Systems ( NASDAQ:MMSI )
Merit Medical Systems's MMSI short percent of float has fallen 4.05% since its last report. The company recently reported that it has 3.27 million shares sold short, which is 7.81% of all regular shares that are available for trading.
Why Is Merit Medical Stock Trading Higher On Tuesday? - Merit Medical Systems ( NASDAQ:MMSI )
Q2 revenue expected to exceed analyst estimates with up to 14% growth. Analyst reaffirms Buy rating, sets $108 price forecast for MMSI. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On Merit Medical Systems Inc.
Merit Medical Names Martha Aronson as New President and Chief Executive Officer - Merit Medical Systems ( NASDAQ:MMSI )
Fred Lampropoulos will continue to serve as Chairman of Merit's Board of Directors Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025 SOUTH JORDAN, Utah, July 07, 2025 ( GLOBE NEWSWIRE ) -- Merit Medical Systems, Inc.
Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025
SOUTH JORDAN, Utah, July 03, 2025 ( GLOBE NEWSWIRE ) -- Merit Medical Systems, Inc. ( NASDAQ: MMSI ) , a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2025, after the close of the stock ...
What Does the Market Think About Merit Medical Systems? - Merit Medical Systems ( NASDAQ:MMSI )
Merit Medical Systems's MMSI short percent of float has fallen 4.08% since its last report. The company recently reported that it has 3.15 million shares sold short, which is 7.52% of all regular shares that are available for trading.
President and CEO At Merit Medical Systems Sells $951K Of Stock - Merit Medical Systems ( NASDAQ:MMSI )
Fred Lampropoulos, President and CEO at Merit Medical Systems MMSI, disclosed an insider sell on June 3, according to a recent SEC filing. What Happened: Lampropoulos's decision to sell 10,000 shares of Merit Medical Systems was revealed in a Form 4 filing with the U.S.
Here's How Much $1000 Invested In Merit Medical Systems 20 Years Ago Would Be Worth Today - Merit Medical Systems ( NASDAQ:MMSI )
Merit Medical Systems MMSI has outperformed the market over the past 20 years by 1.28% on an annualized basis producing an average annual return of 9.54%. Currently, Merit Medical Systems has a market capitalization of $5.58 billion.
MMSI Stock Gains Following Latest Merger to Boost Hemostasis Portfolio
Merit Medical aims to provide an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology.
Merit Medical Acquires Biolife Delaware, L.L.C.
SOUTH JORDAN, Utah, May 20, 2025 ( GLOBE NEWSWIRE ) -- Merit Medical Systems, Inc. ( NASDAQ: MMSI ) , a global leader of healthcare technology, today announced that it has acquired Biolife Delaware, L.L.C. ( "Biolife" ) in a merger transaction through which Biolife has become a wholly-owned ...
Merit Medical Acquires Biolife Delaware, L.L.C. - Merit Medical Systems ( NASDAQ:MMSI )
Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit's portfolio supports.
Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
SOUTH JORDAN, Utah, May 06, 2025 ( GLOBE NEWSWIRE ) -- Merit Medical Systems, Inc. ( NASDAQ: MMSI ) , a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis ( CIE ) received regulatory approval from Health Canada.
Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis - Merit Medical Systems ( NASDAQ:MMSI )
The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients. Approval was supported by superior 12-month target lesion primary patency ( 70.1% ) and access circuit primary patency ( 58.1% ) in the randomized arm of the trial.
Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft ( AVG ) Cohort of the WRAPSODY® Arteriovenous Efficacy ( WAVE ) Trial
In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis ( CIE ) achieved 60.2% target lesion primary patency ( TLPP ) at 12 months. In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis ( CIE ) achieved 60.2% target ...
Can Sustained Product Demand Drive BDX Stock Before Q2 Earnings?
The continued solid uptake of BD's products is expected to have driven fiscal second-quarter revenues despite transitory market dynamics.
MMSI Stock Declines Despite Q1 Earnings Beating Estimates, Margins Up
Merit Medical benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter of 2025.
$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today - Merit Medical Systems ( NASDAQ:MMSI )
Merit Medical Systems MMSI has outperformed the market over the past 20 years by 2.48% on an annualized basis producing an average annual return of 10.32%. Currently, Merit Medical Systems has a market capitalization of $5.38 billion.
Will Segmental Performance Drive West Pharmaceutical's Q1 Earnings?
West Pharmaceutical Services' first-quarter results are likely to reflect growth amid pharma stabilization, biologics rebound & contract manufacturing gains.
Merit Medical Stock Slips Despite the Launch of New Ventrax System
MMSI launches the Ventrax Delivery System, enhancing pulmonary access procedures with improved control, precision, and efficiency for interventionalists.
4 Stocks to Watch as Dental Supplies Recovers Amid Tariff Headwind
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are CAH, MMSI, XRAY and CNMD.
US-China Trade Tensions Poses Risk To Merit Medical's $150 Million Revenue From China - Merit Medical Systems ( NASDAQ:MMSI )
Q1 2025 EPS projected at $0.75, revenue expected at $352.82 million FY25 EPS seen at $3.58-$3.70 vs. $3.74 consensus, revenue guided to $1.47-$1.49 billion. China's new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt Maley.
Merit Medical Launches the Ventrax™ Delivery System
Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia ...
Merit Medical Launches the Ventrax™ Delivery System - Merit Medical Systems ( NASDAQ:MMSI )
SOUTH JORDAN, Utah, April 09, 2025 ( GLOBE NEWSWIRE ) -- Merit Medical Systems, Inc. MMSI, a global leader in healthcare technology, today announced the US commercial release of its Ventrax Delivery System.
Merit Medical Systems to Announce First Quarter 2025 Results on April 24, 2025
SOUTH JORDAN, Utah, April 07, 2025 ( GLOBE NEWSWIRE ) -- Merit Medical Systems, Inc. ( NASDAQ: MMSI ) , a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2025, after the close of the ...
Merit Medical Systems to Announce First Quarter 2025 Results on April 24, 2025 - Merit Medical Systems ( NASDAQ:MMSI )
SOUTH JORDAN, Utah, April 07, 2025 ( GLOBE NEWSWIRE ) -- Merit Medical Systems, Inc. MMSI, a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2025, after the close of the stock market on ...
How Do Investors Really Feel About Merit Medical Systems? - Merit Medical Systems ( NASDAQ:MMSI )
Merit Medical Systems's MMSI short percent of float has risen 7.66% since its last report. The company recently reported that it has 3.24 million shares sold short, which is 8.01% of all regular shares that are available for trading.
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
Merit Medical's strong product portfolio raises optimism about the stock.
GE HealthCare's Latest Product Launch to Boost Cardiology Care
GEHC's latest commercial launch of Flyrcado and the grant of pass-through status by CMS aim to serve a wider patient pool across the United States.
Bitcoin Falls To $85K, Altcoins Drop Ahead Of Inflation Data; Trump's Tariffs May Raise $800B, But Risks Loom; Tesla Faces EV Incentive Cuts In UK After Canada - Top Headlines While The U.S. Slept
Galaxy Digital To Pay $200 Million In Terra-LUNA Settlement With New York Attorney General Bitcoin Down To $85,000, Ethereum, XRP Slide 5% Before Key Inflation Data Trump's SEC Pick Paul Atkins Says His 'Top Priority' Will Be 'Rational' Crypto Regulations, Marking Shift From Gary Gensler's Approach
This Merit Medical Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Integer Holdings ( NYSE:ITGR ) , Getty Realty ( NYSE:GTY )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keefe, Bruyette & Woods analyst Ryan Tomasello initiated coverage on Zillow Group, Inc.
Updated ASGE Clinical Practice Guideline Includes TIF 2.0 and cTIF for Management of GERD
Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms. Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms.
Merit Medical Stock May Rise as WRAPSODY CIE Shows Strong Results
MMSI unveils 12-month efficacy data for WRAPSODY CIE, highlighting its advanced technology in vascular access maintenance and potential to improve patient outcomes.
Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis ( CIE )
SOUTH JORDAN, Utah, March 25, 2025 ( GLOBE NEWSWIRE ) -- Merit Medical Systems, Inc. ( NASDAQ: MMSI ) , a global leader of healthcare technology, today announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy ( WAVE ) trial are scheduled for ...
Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis ( CIE ) - Merit Medical Systems ( NASDAQ:MMSI )
At 6 months, the WRAPSODY CIE achieved 89.8% and 72.6% target lesion primary patency and access circuit primary patency, respectively. At 12 months, the WRAPSODY CIE achieved 70.1% and 58.1% target lesion primary patency and access circuit primary patency, respectively.
Stereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?
The collaboration, highlighted at NVIDIA's GTC conference, aims to integrate artificial intelligence into surgical robotics, potentially enhancing Stereotaxis' technological capabilities.
Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership
SOUTH JORDAN, Utah, March 18, 2025 ( GLOBE NEWSWIRE ) -- Merit Medical Systems, Inc. ( NASDAQ: MMSI ) , a global leader of healthcare technology, announced that Chairman and Chief Executive Officer, Fred Lampropoulos, will visit the Nasdaq MarketSite in Times Square to ring the opening bell on ...
Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership - Merit Medical Systems ( NASDAQ:MMSI )
SOUTH JORDAN, Utah, March 18, 2025 ( GLOBE NEWSWIRE ) -- Merit Medical Systems, Inc. MMSI, a global leader of healthcare technology, announced that Chairman and Chief Executive Officer, Fred Lampropoulos, will visit the Nasdaq MarketSite in Times Square to ring the opening bell on Wednesday, ...
MMSI Announces Commencement of Patient Enrollment in PREEMIE Study
Merit Medical aims to improve care for vulnerable premature infants by evaluating the safety and efficacy of the Bloom Micro Occluder System for treating PDA in the specified patient pool.
First Patient Enrolled in Merit Medical's PREEMIE Study
Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ...
Insider Selling: FRED LAMPROPOULOS Unloads $3.56M Of Merit Medical Systems Stock - Merit Medical Systems ( NASDAQ:MMSI )
Disclosed on March 6, FRED LAMPROPOULOS, President and CEO at Merit Medical Systems MMSI, executed a substantial insider sell as per the latest SEC filing. What Happened: LAMPROPOULOS's decision to sell 34,319 shares of Merit Medical Systems was revealed in a Form 4 filing with the U.S.
MMSI Stock Gains in Pre-Market Post Q4 Earnings Beat, Margins Up
Merit Medical benefits from revenue growth in both segments and all its product categories within its Cardiovascular unit in the fourth quarter of 2024.
The Zacks Analyst Blog Highlights Fresenius Medical, Masimo, Merit Medical Systems and Inogen
Fresenius Medical, Masimo, Merit Medical Systems and Inogen are included in this Analyst Blog.
